With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3779-42-8,3-Bromo-N,N,N-trimethylpropan-1-aminium bromide,as a common compound, the synthetic route is as follows.
Compound 14 (50 mg, 0.05 mmol) is dissolved and K2C03 (150 mg, 1.1 mmol) is suspended in DMF (30 mL). To the vigorously-stirred mixture a solution of (1-BROMOPROPYL)-TRIMETHYLAMMONIUM bromide (0.3 g, 16.6 mmol) in DMF (10 mL) is added dropwise at 50C and the mixture is heated for 18 h. After removal of DMF under high vacuum, the residue obtained is dissolved in methanol (5 ML) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 CM). After washing the pad with methanol (ca. 500 mL) it is eluted with acetic acid: methanol: water (3: 2: 1, by vol. ). After evaporation of solvent from appropriate combined fractions the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting with n-butanol: water: acetic acid (5: 4: 1, by vol. , upper phase) for further separation from the excess ammonium salt and other by-products. After removal of solvent under reduced pressure the residue obtained is dissolved in methanol and passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). After evaporation of solvent under reduced pressure, the product is dried under high vacuum. 1 H-NMR : sH (300MHZ, CD30D): 0.80 (t, 3J 7.5 Hz, 6 H), 1.15-1. 35 (m, 28 H), 1.35-1. 45 (bs, 4 H), 1.70-1. 80 (bs, 4 H), 2.30-2. 40 (BS, 4 H), 3.15-3. 30 (bs, 18 H), 3.65-3. 75 (bs, 4 H), 4.00-4. 05 (m, 4 H), 4.30-4. 40 (bs, 4 H), 7.00-7. 15,7. 20-7.30, 7. 80-95, 7.95-8. 15 (4 x m, 4 x 4 H), 8.60-9. 00 (bs, 8 H)., 3779-42-8
3779-42-8 3-Bromo-N,N,N-trimethylpropan-1-aminium bromide 151145, acatalyst-ligand compound, is more and more widely used in various fields.
Reference£º
Patent; DESTINY PHARMA LIMITED; SOLVIAS AG; WO2004/56828; (2004); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI